Search Results
Your search for ,ALl matches 18393 pages
Showing 2001 - 2050Annual Increases in Cardiorespiratory Fitness May Help Reduce Risk of Prostate Cancer
An increase in annual cardiorespiratory fitness may be linked to a lower risk of developing prostate cancer, according to a recent study published by Bolam et al in the British Journal of Sports Medicine. Background There are relatively few known risk factors for prostate cancer. Although research...
Accelerated Hypofractionated Chemoradiation With Adaptive SABR Boost in Locally Advanced, Unresectable NSCLC
In a U.S. single-center radiation dose-expansion study reported in JAMA Oncology, Wu et al found that chemoradiation with adaptively increased stereotactic ablative radiotherapy (SABR) boost doses was safe and effective in patients with locally advanced, unresectable non–small cell lung cancer...
Colon Cancer Mortality Rates: Predictions Across the European Union and United Kingdom
Investigators discovered that overweight and obesity may be contributing to rising rates of colon cancer mortality in younger patients, according to a recent study published by Santucci et al in the Annals of Oncology. The findings represent the first time colon cancer mortality rates among younger ...
Is HRR Testing Underused in Patients With Prostate Cancer?
Despite being recommended in prostate cancer guidelines, homologous recombinant repair (HRR) mutation analysis is widely underused in patients with prostate cancer, according to real-world data presented at the 2024 ASCO Genitourinary Cancers Symposium (Abstract 210). A major implication of these...
UICC Offers Recommendations in Preparation for World Cancer Day 2024
The Union for International Cancer Control (UICC) has provided a new set of recommendations to eliminate inequities in cancer care in light of World Cancer Day on February 4, according to the new World Cancer Day 2024 Equity Report. Background Since its establishment in 2000, World Cancer Day has...
Use of Adjuvant Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma: CheckMate 274
Subsequent systemic therapy with the immune checkpoint inhibitor nivolumab may offer overall survival benefit in patients with muscle-invasive urothelial carcinoma who underwent surgery to remove their tumors, according to recent findings presented by Geynisman et al at the 2024 ASCO Genitourinary...
More Intensified Salvage Regimen for Prostate Cancer Does Not Impair Health-Related Quality of Life
In patients with biochemically recurrent prostate cancer after radical prostatectomy, a more intensified regimen of abiraterone acetate/prednisone plus apalutamide improved outcomes and did not lead to decrements in specific domains of health-related quality of life (HRQoL) vs treatment with...
Cervical Cancer Rates May Be Rising in Low-Income U.S. Counties
The incidence and mortality of cervical cancer may be rising in patients residing in low-income areas of the United States, according to a recent study published by Amboree et al in the International Journal of Cancer. Study Methods and Results In the recent study, investigators used the...
Secondary Cancers May Be Rare in Patients Treated With CAR T-Cell Therapy
The development of any type of secondary cancer following chimeric antigen receptor (CAR) T-cell therapy may be rare, according to a recent study published by Ghilardi et al in Nature Medicine. Background Secondary cancers, including T-cell lymphomas, are known risks of cancer treatments such as...
Intensified vs Standard Induction in Younger Patients With Newly Diagnosed AML
In a UK trial (NCRI AML19) reported in the Journal of Clinical Oncology, Russell et al found that intensified induction therapy with FLAG-Ida (fludarabine, cytarabine, granulocyte colony–stimulating factor, and idarubicin) plus gemtuzumab ozogamicin did not improve overall survival in younger...
Cabozantinib and Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Patients with metastatic castration-resistant prostate cancer with extrapelvic nodal or visceral metastasis who were treated with the combination of cabozantinib plus atezolizumab had significantly improved time to disease progression compared with those who were treated with hormonal therapy. This ...
Generic Drug Shortages and Essential Cancer Medicines
Decisions regarding the rationing of chemotherapy are commonplace in many countries around the world—including those where patients must pay for chemotherapy out of pocket—and increasingly so in cancer settings that treat both well-off and socioeconomically disadvantaged patients. However, these...
2023 ASCO Advocacy Highlights
The Association for Clinical Oncology (ASCO) had an immensely impactful year of advocacy work, which is possible only with guidance and passion from our members. In partnership with the ASCO’s Government Relations Committee, five advocacy priorities were identified for the year: Protecting...
OVHIPEC-1 Trial: Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Improves Survival in Advanced Ovarian Cancer
The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...
Expert Point of View: Heather Han, MD
Heather Han, MD, Research Director, Department of Breast Oncology, Moffitt Cancer Center, Tampa, commented on the latest update from the NATALEE trial: “Despite the established standard adjuvant therapy, many patients with hormone receptor–positive, early-stage breast cancer (including stages...
NATALEE Trial: Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer
Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone....
Expert Point of View: Cynthia E. Dunbar, MD
In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...
SYMPATICO Trial: Ibrutinib Plus Venetoclax Improves Progression-Free Survival in Relapsed Mantle Cell Lymphoma
The combination of ibrutinib and venetoclax has led to an improved progression-free survival rate in patients with relapsed or refractory mantle cell lymphoma (MCL), according to findings presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Interim analysis...
Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?
A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...
Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Real-World Experience Mirrors PERSEUS Findings
At the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers from Emory University presented a real-world comparison of the largest cohort of patients with newly diagnosed multiple myeloma consecutively treated with either bortezomib, lenalidomide, and dexamethasone ...
Additional Analysis of MATTERHORN Confirms Global Benefit of Durvalumab Plus FLOT in Gastric/Gastroesophageal Junction Cancer
Subgroup analyses of the randomized double-blind phase III MATTERHORN trial continue to show the benefit of adding perioperative durvalumab to standard chemotherapy in patients with locally advanced, resectable gastric or gastroesophageal junction cancer. Detailed findings on pathologic complete...
Use of Direct Oral Anticoagulant Agents in Active Cancer: Meta-Analysis
In a systematic review and meta-analysis reported in JACC: CardioOncology, Fujisaki et al found no significant differences among direct oral anticoagulant agents (DOACs) in the prevention of recurrent venous thromboembolism (VTE) associated with active cancer, whereas significant differences in...
FDA Issues Safety Labeling Change Notification to CAR T-Cell Therapy Manufacturers
On January 19, the U.S. Food and Drug Administration (FDA) issued safety labeling change notification letters to all manufacturers of licensed B-cell maturation antigen (BCMA)-directed and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell immunotherapies requiring ...
Melanoma Overdiagnoses May Be Rising Among White U.S. Patients
Over 50% of all melanoma diagnoses among White patients in the United States may in fact be overdiagnoses, according to a recent study published by Adamson et al in BMJ Evidence-Based Medicine. Background “Cases of cutaneous melanoma have risen significantly in the [United States] over the last 40...
My Breast Cancer Experience Has Led Me to Leverage My Expertise in Human-Centered Design to Transform Patient Care
The road to my breast cancer diagnosis in 2018 was long and tortuous. For 3 years leading up to the diagnosis, I had imaging scans and tissue biopsies every 3 months because of suspicious masses in my breasts. The uncertainty was so destabilizing that I was in a constant state of emotional unrest....
Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...
The High Cost of Oral Agents for Relapsed and Refractory Multiple Myeloma
Late in 2023, Richardson et al shared the results of a phase I/II clinical trial (ClinicalTrials.gov identifier NCT03374085). They concluded that the “all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma.”1 Mezigdomide ...
Long-Term Follow-up of KEYNOTE-590: Benefit of Pembrolizumab Plus Chemotherapy Affirmed in Advanced Esophageal Cancer
Long-term follow-up of the phase III KEYNOTE-590 trial has confirmed the benefit of pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median follow-up of almost 59 months, patients treated with the chemoimmunotherapy combination were three...
First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...
Expert Point of View: Rory M. Shallis, MD
Rory M. Shallis, MD, Assistant Professor of Medicine (Hematology) at Yale School of Medicine, shared his thoughts on the use of revumenib in histone-lysine N-methyltransferase 2A-rearranged (KMT2A-rearranged) leukemia, as reported in the phase II AUGMENT-101 trial. In an interview with The ASCO...
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...
New Director of the University of Hawaii Cancer Center, Naoto T. Ueno, MD, PhD, FACP, Is Also a Two-Time Cancer Survivor
In this installment of The ASCO Post ’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Naoto T. Ueno, MD, PhD, FACP, Director of the University of Hawaii Cancer Center. Along with his duties leading the cancer center, Dr. Ueno leads translational breast cancer research...
Antiemetic Strategies for Patients Receiving Highly Emetogenic Chemotherapy
In an Indian single-center phase III trial reported in The Lancet Oncology, Bajpai et al found that low-dose olanzapine was noninferior to standard-dose olanzapine plus triple antiemetic therapy in terms of antiemetic efficacy and reduced daytime somnolence in patients with solid tumors receiving...
Novel Molecular Twin Tool May Improve Precision Medicine Care in Patients With Pancreatic Cancer
The novel artificial intelligence (AI)-based Molecular Twin Precision Oncology Platform may be capable of identifying biomarkers that may outperform the standard test for predicting pancreatic cancer survival, according to a recent study published by Osipov et al in Nature Cancer. Background...
Beyond Lung Cancer: Leveraging Machine Learning Techniques to Understand Other Diseases
Although computed tomography (CT) screening has emerged as an essential tool for the early detection of lung diseases, there is still a broad range of potential improvements to be made. According to recent research, understanding the patterns of onset for earlier prediction of disease may be...
Tackling the Challenges of Oncology Workforce Shortages, Increased Patient Demand, and Rising Costs of Care
In May 2023, The ASCO Post launched a new feature, View From the Top: The Future of Cancer Care Delivery, which explores how leaders in oncology are developing strategies to ensure continued innovative oncology care in an ever-changing health-care environment. In this installment, Guest Editor Jame ...
NETTER-2: Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors
Results from the first phase III clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with lutetium Lu-177 dotatate significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic...
Standard vs Histology-Tailored Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma
In an expanded cohort of a European trial reported in the Journal of Clinical Oncology, Alessandro Gronchi, MD, and colleagues found that histology-tailored neoadjuvant chemotherapy with trabectedin was noninferior in terms of disease-free survival to standard neoadjuvant anthracycline/ifosfamide...
Addition of Cetuximab Maintenance to First-Line FOLFIRI/Cetuximab in RAS/BRAF Wild-Type Colorectal Cancer
As reported in the Journal of Clinical Oncology by Pinto et al, the Italian phase III ERMES trial showed that the addition of cetuximab maintenance to eight cycles of first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus cetuximab did not achieve noninferiority in terms of...
Novel PI3K Inhibitor as Part of Triplet Improves Outcomes in Hormone Receptor–Positive, HER2-Negative Breast Cancer
The addition of inavolisib to first-line treatment with palbociclib plus fulvestrant more than doubled progression-free survival in patients with recurrent PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer, according to a late-breaking primary analysis of the phase III ...
Normal Risk Ovarian Screening Study: Long-Term Update
As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details The NROSS...
Undocumented Cost-of-Care Discussions: A Missed Opportunity in Cancer Treatment
A recent study underscored the need for integrating cost-of-care conversations in cancer treatment. Results of the population-based analysis, presented at the 2023 ASCO Quality Care Symposium,1 showed that only about 25% of patients with newly diagnosed advanced non–small cell lung cancer (NSCLC)...
MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD) status and related outcomes among patients receiving obinutuzumab- and rituximab-based treatment for previously untreated follicular lymphoma. Study...
Harinder Gill, MD, MBBS, on Acute Promyelocytic Leukemia: Assessing the Use of Oral Arsenic Trioxide, Retinoic Acid, and Ascorbic Acid
Harinder Gill, MD, MBBS, of The University of Hong Kong, discusses findings showing the use of an “AAA” regimen (pure oral arsenic trioxide combined with all-trans retinoic acid) in a risk-adapted strategy that minimized chemotherapy was highly effective and safe in patients with newly diagnosed...
Jeffrey E. Rubnitz, MD, PhD, on Pediatric AML Outcomes and Racial Disparities
Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap ...
Young Women With Breast Cancer: Discussing vs Pursuing Fertility Preservation
In 2023, nearly 300,000 new cases of invasive breast cancer were diagnosed in the United States, and approximately 56,000 new cases of ductal carcinoma in situ were diagnosed. Although most of those cancers are diagnosed in older adults, about 9% of all new cases of breast cancer are found in women ...
Genetic Identification of Women at Lower Risk of Breast Cancer
In a retrospective analysis reported in JAMA Oncology, Bolze et al identified a group of women at low risk for breast cancer based on genetic analysis. The findings may support altering cancer screening in this low-risk group. As stated by the investigators, “Genetic information is not being used...
Novel Risk Model May Personalize Prognosis Prediction in Patients With Multiple Myeloma
Researchers have developed a novel computational model for personalized prognosis prediction in patients with newly diagnosed multiple myeloma, according to a new study published by Maura et al in the Journal of Clinical Oncology. Their model for individualized risk in multiple myeloma, or IRMMa,...
